Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy

Acta Radiologica

Volumn 50, Issue 7, 2009, Pages 716-721

  Knudsen, Anders Riegels ^a   Kannerup, Anne Sofia ^a   Mortensen, Frank Viborg ^a   Nielsen, Dennis Tønner ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Abdomen GI; Ablation procedures; Adults; CT; Liver; Metastases

Indexed keywords

5-FLUOROURACIL; ABDOMEN/GI; ADULTS; CT; IRINOTECAN; LIVER METASTASIS; MEDIAN SURVIVAL; METASTASES; MULTI-DISCIPLINARY TEAMS; MULTIDETECTOR COMPUTED TOMOGRAPHY; OXALIPLATIN; POST TREATMENT; RADIOFREQUENCY ABLATION; SURVIVAL RATE; UP PERIOD;

ABLATION; CHEMOTHERAPY; COMPUTERIZED TOMOGRAPHY; DIAGNOSIS; LIVER; PATIENT MONITORING; TOMOGRAPHY; TUMORS;

PATHOLOGY;

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX;

AGED; ARTICLE; CATHETER ABLATION; COLORECTAL TUMOR; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LIVER TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOGRAPHY; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CATHETER ABLATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 69949182373     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1080/02841850902991634     Document Type: Article

References (28)

1. Fong Y, Kemeny N, Paty P, Blumgart LH, Cohen AM. Treatment of colorectal cancer: hepatic metastasis. Semin Surg Oncol 1996;12:219-52.
2. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938-46.
3. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-18.
4. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989;210:127-38.
5. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007;11: 1057-77.
6. Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 2002;38:1023-33.
7. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, et al. radio frequency ablation of unresect-able primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 1999;230:1-8.
8. de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, et al. Radio frequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. Am J Roentgenol 2000;175:1619-25.
9. Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radio frequency ablation of colorectal liver metas-tases: 10-year experience. Ann Surg 2007;246:559-65.
10. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors withpercutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003;226:441-51.
11. Hildebrand P, Kleemann M, Roblick UJ, Mirow L, Birth M, Leibecke T, et al. Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients. Langenbecks Arch Surg 2006; 391:118-23.
12. Amersi FF, McElrath-Garza A, Ahmad A, Zogakis T, Allegra DP, Krasne R, et al. Long-term survival after radio frequency ablation of complex unresectable liver tumors. Arch Surg 2006; 141:581-7.
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
14. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
15. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-9.
16. Alberts SR, HorvathWL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, et al. Oxaliplatin, fluorour-acil, and leucovorin for patients withunresectable liver-only metastases from colorectal cancer: a NorthCentral Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243-9.
17. Kohne CH, van Cutsem CE, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid withor without irinotecan in patients with metastatic colorectal cancer: European Organisation for Researchand Treat- ment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23:4856-65.
18. Rappeport ED, Loft A, Berthelsen AK, von der Recke RP, Larsen PN, Mogensen AM, et al. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients withliver metastases from colorectal cancer: a prospective study withintraopera-tive confirmation. Acta Radiol 2007;48:369-78.
19. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOL-FOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
20. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-57.
21. Poston GJ, Figueras J, Giuliante F, Nuzzo G, Sobrero AF, Gigot JF, et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008; 26:4828-33.
22. Sorensen SM, Mortensen FV, Nielsen DT. Radio-frequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 2007;48:253-8.
23. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001;221: 159-66.
24. Berber E, Tsinberg M, Tellioglu G, Simpfendorfer CH, Siperstein AE. Resection versus laparoscopic radio-frequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 2008;12:1967-72.
25. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic color-ectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:1271-80.
26. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepa-tectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8.
27. Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969;23:198-202.
28. Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit K, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients withmetastatic colorectal cancer. Ann Oncol 2008;19:909-14.